(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.09% HKD 2.77
Live Chart Being Loaded With Signals
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China...
Stats | |
---|---|
Dzisiejszy wolumen | 39.49M |
Średni wolumen | 52.37M |
Kapitalizacja rynkowa | 50.97B |
EPS | HKD0 ( 2024-03-29 ) |
Następna data zysków | ( HKD0 ) 2024-06-14 |
Last Dividend | HKD0.0600 ( 2023-06-20 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 25.18 |
ATR14 | HKD0.00800 (0.29%) |
Wolumen Korelacja
Sino Biopharmaceutical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sino Biopharmaceutical Korelacja - Waluta/Towar
Sino Biopharmaceutical Finanse
Annual | 2023 |
Przychody: | HKD26.20B |
Zysk brutto: | HKD21.21B (80.95 %) |
EPS: | HKD0.0997 |
FY | 2023 |
Przychody: | HKD26.20B |
Zysk brutto: | HKD21.21B (80.95 %) |
EPS: | HKD0.0997 |
FY | 2022 |
Przychody: | HKD28.78B |
Zysk brutto: | HKD22.98B (79.86 %) |
EPS: | HKD0.270 |
FY | 2021 |
Przychody: | HKD26.86B |
Zysk brutto: | HKD21.53B (80.15 %) |
EPS: | HKD0.780 |
Financial Reports:
No articles found.
Sino Biopharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0600 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0600 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00198 | 2004-09-16 |
Last Dividend | HKD0.0600 | 2023-06-20 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 70 | -- |
Total Paid Out | HKD0.573 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.91 | -- |
Div. Sustainability Score | 9.59 | |
Div.Growth Potential Score | 5.14 | |
Div. Directional Score | 7.37 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2270.HK | Ex Dividend Junior | 2023-06-26 | Insufficient data to determine frequency | 0 | 0.00% | |
1263.HK | Ex Dividend Junior | 2023-09-14 | Annually | 0 | 0.00% | |
0321.HK | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
6030.HK | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
1818.HK | Ex Dividend Junior | 2023-06-07 | Annually | 0 | 0.00% | |
0848.HK | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
0006.HK | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
2588.HK | Ex Dividend Knight | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
1382.HK | Ex Dividend Knight | 2023-08-15 | Semi-Annually | 0 | 0.00% | |
0455.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0711 | 1.500 | 8.58 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0247 | 1.200 | 9.18 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0519 | 1.500 | -0.534 | -0.801 | [0.1 - 1] |
payoutRatioTTM | 0.404 | -1.000 | 5.96 | -5.96 | [0 - 1] |
currentRatioTTM | 1.053 | 0.800 | 9.73 | 7.79 | [1 - 3] |
quickRatioTTM | 0.755 | 0.800 | -0.263 | -0.210 | [0.8 - 2.5] |
cashRatioTTM | 0.418 | 1.500 | 8.79 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.197 | -1.500 | 6.72 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.196 | 2.00 | 9.93 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.142 | 2.00 | 9.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.410 | -1.500 | 8.36 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.788 | 1.000 | 0.197 | 0.197 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.203 | 1.000 | 7.94 | 7.94 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.306 | 1.000 | 9.41 | 9.41 | [0.2 - 2] |
assetTurnoverTTM | 0.347 | 0.800 | -1.020 | -0.816 | [0.5 - 2] |
Total Score | 9.59 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 31.82 | 1.000 | 6.89 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0519 | 2.50 | -0.343 | -0.801 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.142 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.12 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.196 | 2.00 | 9.93 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.404 | 1.500 | 5.96 | -5.96 | [0 - 1] |
pegRatioTTM | 0.329 | 1.500 | -1.141 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.174 | 1.000 | 8.16 | 0 | [0.1 - 0.5] |
Total Score | 5.14 |
Sino Biopharmaceutical
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej